DispersinB(R) Topical Wound Gel Passes First Set Of Biocompatibility Tests

Main Category: Pharma Industry / Biotech Industry
Article Date: 29 Sep 2009 - 20:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant. The other FDA-recommended biocompatibility tests (sensitization, genotoxicity and sub-chronic toxicity) are currently in progress.

In addition, the University of Medicine and Dentistry of New Jersey has also studied the cytotoxicity of research grade DispersinB® enzyme under Non-GLP conditions.

"We have tested the in vitro cytotoxicity of DispersinB® enzyme using human and mouse cell lines and DispersinB® enzyme showed negligible or no cytotoxicity against the cultured cell lines under the conditions tested," stated Dr. Jeffrey B. Kaplan, the discoverer of the DispersinB enzyme and Associate Professor, Department of Oral Microbiology, University of Medicine and Dentistry of New Jersey, Newark, NJ. "The clinical grade DispersinB® cytotoxicity test results from WuXi AppTec confirm our findings that DispersinB® is non-cytotoxic," concluded Dr. Kaplan.

"Although DispersinB® is a naturally occurring enzyme produced by one of the oral bacteria, it is important to demonstrate its safety for human applications using a battery of FDA-recommended biocompatibility tests," stated Dr. Sri Madhyastha, Vice-President, Research & Chief Scientific Officer of Kane Biotech Inc. "After completing all the tests, the biocompatibility data will be used to prepare the FDA Investigational Device Exemption (IDE) package for submission".

Source
Kane Biotech Inc.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kane Biotech Inc. "DispersinB(R) Topical Wound Gel Passes First Set Of Biocompatibility Tests." Medical News Today. MediLexicon, Intl., 29 Sep. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/165558.php>

APA
Kane Biotech Inc. (2009, September 29). "DispersinB(R) Topical Wound Gel Passes First Set Of Biocompatibility Tests." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/165558.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »